This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Dutasteride capsules 500 micrograms


Oral formulations of dutasteride.

Drugs List

  • AVODART 500microgram capsules
  • dutasteride 500microgram capsules
  • Therapeutic Indications


    Benign prostatic hyperplasia

    Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH).

    Reduction in risk of surgery and acute urinary retention in patients with moderate to severe symptoms of BPH.



    500 micrograms once daily.


    Children under 18 years
    Severe hepatic impairment

    Precautions and Warnings

    Mild hepatic impairment

    Some products may contain soya or soya derivative
    Absorbed by skin - avoid contact with leaking capsules
    Evaluate for prostate cancer before and during treatment
    Combination with alpha blocker: Increased incidence of cardiac failure
    Establish new PSA baseline at 6 months and monitor PSA regularly thereafter
    Investigate any sustained increase in PSA during treatment
    Advise patient to report any breast changes e.g. lumps, pain or discharge
    Causes a decrease in serum prostate specific antigen (PSA) by approx. 50%
    Advise patient grapefruit products may increase plasma level
    May reduce sperm count, function, motility or seminal fluid volume
    Male: Use of condoms advised if partner pregnant or may become pregnant

    Pregnancy and Lactation


    Not indicated for use in women.

    Dutasteride inhibits the conversion of testosterone to dihydrotestosterone and may, if administered to a women carrying a male foetus, inhibit the development of the external genitalia of the foetus.

    Small amounts of dutasteride have been found in the semen of men undergoing treatment. It is not known if a male foetus may be adversely affected if his mother is exposed to the semen of a patient being treated with dutasteride, however the risk would be higher during the first 16 weeks of pregnancy.


    Not indicated for use in women.

    It is not known whether dutasteride is excreted in human milk.


    Advise patient that dutasteride is absorbed through the skin and that women and children must avoid contact with leaking capsules. If contact is made with leaking capsules, the contact area should be washed immediately with soap and water.

    Advise patients capsules should be swallowed whole and not chewed or opened as contact with the capsule contents may result in irritation of the oropharyngeal mucosa.

    Advise patient grapefruit products may increase plasma level of dutasteride.

    Advise patients to report any changes in their breast tissue such as lumps or nipple discharge.

    If the patient's partner is or may potentially be pregnant, it is recommended that the patient avoids exposure of his partner to semen by use of a condom.

    Side Effects

    Allergic reaction
    Breast enlargement
    Breast tenderness
    Depressed mood
    Ejaculation disorders
    Reduced libido


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2019

    Reference Sources

    Summary of Product Characteristics: Avodart 0.5mg soft capsules. GlaxoSmithKline UK. Revised November 2017.
    Summary of Product Characteristics: Dutasteride 0.5mg soft capsules. Accord Healthcare Ltd. Revised May 2019.
    Summary of Product Characteristics: Avodart 0.5mg soft capsules. Dr Reddys Laboratories Ltd. Revised May 2016.
    Summary of Product Characteristics: Zepron 0.5mg soft capsules. Ennogen Healthcare UK. Revised December 2017.

    NICE Evidence Services Available at: Last accessed: 22 July 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.